SCENESSE: Uses, Dosage & Side Effects
A melanocortin-1 receptor agonist delivered as a subcutaneous implant, approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP)
SCENESSE (afamelanotide) is a first-in-class melanocortin-1 receptor (MC1R) agonist used to prevent phototoxic reactions in adults with erythropoietic protoporphyria (EPP), a rare inherited metabolic disorder of the haem biosynthesis pathway. Afamelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that stimulates epidermal melanocytes to produce eumelanin, the dark photoprotective form of melanin. By increasing the density of eumelanin in the skin, SCENESSE raises patients' tolerance to visible and ultraviolet light and reduces the severity and frequency of the extremely painful skin reactions that define EPP. The medicine is supplied as a small sterile implant containing 16 mg of afamelanotide, which a specialist physician inserts under the skin above the hip, where it gradually releases active substance for approximately two months. SCENESSE is a prescription-only, specialist-administered treatment and is the first systemic therapy ever approved specifically for EPP.
Quick Facts: SCENESSE
Key Takeaways
- SCENESSE (afamelanotide) is the first medicine specifically approved to prevent phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare genetic disorder that causes severe skin pain on exposure to visible light and some ultraviolet radiation.
- It acts as a melanocortin-1 receptor agonist, stimulating epidermal melanocytes to produce eumelanin (dark photoprotective melanin), which absorbs and scatters light and increases the time patients can tolerate outdoor conditions without phototoxic reactions.
- The medicine is administered by a specially trained specialist physician as a small rod-shaped 16 mg implant inserted under the skin above the anterior iliac crest; one implant is given every two months during periods of anticipated increased sun exposure, up to a maximum of four per year.
- SCENESSE does not eliminate the underlying disease; patients still need to continue their usual sun-protection measures, including protective clothing, avoidance of peak-risk wavelengths, and, where needed, other adjuvant therapies recommended by their porphyria team.
- Careful dermatological monitoring is essential throughout treatment, because afamelanotide increases melanin production and a full-body skin examination every 6 months is recommended to screen for new or changing pigmented and non-pigmented skin lesions.
What Is SCENESSE and What Is It Used For?
SCENESSE contains the active substance afamelanotide, a synthetic tridecapeptide that closely resembles the body's own alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a peptide hormone produced by the pituitary gland and by cells within the skin; it plays a central role in the regulation of pigmentation. When released, alpha-MSH binds to the melanocortin-1 receptor (MC1R) on melanocytes, the specialised skin cells that produce melanin. Activation of MC1R triggers a cascade involving adenylate cyclase and cyclic AMP, which ultimately shifts melanocytes toward the production of eumelanin, the dark-brown photoprotective form of melanin, rather than the red-yellow pheomelanin. Afamelanotide is more metabolically stable than natural alpha-MSH, allowing it to exert a sustained pharmacological effect when released slowly from a subcutaneous implant.
SCENESSE is licensed for the prevention of phototoxicity in adult patients with a confirmed diagnosis of erythropoietic protoporphyria (EPP). EPP is a rare inherited disorder of the haem biosynthesis pathway, most often caused by a reduced activity of the enzyme ferrochelatase, which normally inserts iron into protoporphyrin IX to form haem. When ferrochelatase activity is insufficient, protoporphyrin IX accumulates in red blood cells, plasma and the skin. In the skin, protoporphyrin absorbs photons in the visible and long-ultraviolet spectrum (especially around the 400–410 nm “Soret band”) and generates reactive oxygen species that damage blood vessel walls and surrounding tissue. The clinical result is a phototoxic reaction: intense burning pain, tingling, itching or prickling sensation, followed after some hours or days by erythema, oedema, petechiae, and sometimes crusting of the exposed skin. Unlike a simple sunburn, the pain can begin within minutes of sun exposure and may persist for hours or days after the trigger has ended.
The condition has a profound effect on quality of life. Many patients with EPP organise their days around the avoidance of light, wearing heavy protective clothing, avoiding outdoor activities, declining job opportunities that involve outdoor work, and experiencing considerable psychosocial burden. Standard sun protection, including conventional sunscreens, is often inadequate because most sunscreens are designed to block ultraviolet B and A wavelengths but do not effectively absorb the visible light that triggers EPP reactions. Until the development of SCENESSE, no systemic therapy was specifically approved for the prevention of EPP phototoxicity; treatment consisted mainly of behavioural sun avoidance and adjunctive measures such as beta-carotene or afamelanotide's investigational predecessors with limited effectiveness.
Afamelanotide addresses EPP by increasing the skin's own natural photoprotective pigment. Clinical studies, including the pivotal CUV029, CUV030, CUV039 and CUV017 trials and long-term observational programmes, have shown that regular treatment with SCENESSE significantly increases the time that patients can tolerate direct and indirect sunlight without a phototoxic reaction, reduces the number and severity of phototoxic episodes, and improves patient-reported quality-of-life measures. Data from disease registries across Europe, North America and Australia confirm these benefits in real-world settings, with many patients reporting that they are able to engage in outdoor activities they previously had to avoid completely.
SCENESSE is authorised in the European Union, the United States and several other countries for adult patients with a confirmed EPP diagnosis, established by specific plasma or erythrocyte protoporphyrin measurement and, where relevant, genetic testing. Approval in the EU by the European Medicines Agency came under “exceptional circumstances” given the rarity of the disease, with a requirement for ongoing post-authorisation safety monitoring. In the United States the FDA approved SCENESSE in 2019 following review of its clinical development programme. Regulatory authorities have been clear that SCENESSE should be prescribed and administered only by specially trained physicians working within accredited porphyria centres who can confirm the diagnosis, monitor treatment, and perform the required follow-up dermatological examinations.
SCENESSE is not a general tanning agent or cosmetic product. It is a prescription-only medicinal product approved under strict criteria for a rare, painful and disabling inherited disease. Its use is limited to adults who have received a formal diagnosis of EPP and are managed within a specialist porphyria service.
What Should You Know Before Receiving SCENESSE?
Contraindications
SCENESSE must not be used in the following circumstances. Your doctor will review these carefully before each implant to confirm that treatment remains appropriate.
- Hypersensitivity: Do not use SCENESSE if you are allergic (hypersensitive) to afamelanotide or to any of the other ingredients (see the section on contents below).
- Severe hepatic impairment: SCENESSE should not be used in patients with significant liver disease, including active liver failure, hepatic impairment classified as Child-Pugh B or C, or known portal hypertension, unless the treating specialist determines that the benefits clearly outweigh the risks in an individual case.
- Severe renal impairment: Use of SCENESSE in patients with severe kidney dysfunction has not been studied adequately and should generally be avoided.
Warnings and Precautions
Afamelanotide stimulates melanocytes, the cells that give rise to moles and, in some people, melanoma. Because the medicine is given repeatedly over many years in a chronic disease, a full-body dermatological examination every 6 months is required throughout treatment to screen for new, changing or concerning pigmented or non-pigmented skin lesions. Do not skip these appointments, and tell your porphyria team or dermatologist immediately about any new or changing mole, lesion, or area of unusual skin.
Before starting and during treatment with SCENESSE, discuss the following with your specialist team:
- History of skin cancer or atypical moles: Patients with a personal history of melanoma, non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma), dysplastic naevi syndrome or similar pigmentation disorders require particularly careful evaluation before treatment and closer dermatological surveillance during therapy. SCENESSE is not contraindicated in these patients, but the risk-benefit balance must be assessed individually.
- Pre-existing pigmented lesions: Baseline total body photography or detailed mapping of existing moles is recommended before the first implant to help compare lesions over time. Any lesion that changes in size, shape, colour or symptoms during treatment should be evaluated promptly.
- Cardiovascular disease: SCENESSE has not been studied in patients with unstable or severe cardiovascular disease. If you have known heart disease, hypertension that is not well controlled, a history of stroke or transient ischaemic attack, arrhythmia, or known coronary artery disease, inform your specialist so the risks and benefits can be reviewed.
- Diabetes and metabolic disease: Melanocortin receptors are present on several tissues involved in metabolic regulation. Although afamelanotide is selective for MC1R at therapeutic doses, the safety of SCENESSE has not been fully characterised in patients with poorly controlled diabetes mellitus, obesity with metabolic syndrome, or eating disorders.
- Sun protection must continue: SCENESSE raises the threshold for phototoxicity but does not abolish the underlying EPP. Patients must continue with behavioural sun avoidance, protective clothing, wide-brimmed hats, tinted glasses, and physical sunblocks as advised by their team, particularly during peak daytime hours.
- Implant-site reactions: Redness, bruising, pain, swelling, hyperpigmentation or itching at the implant site are common but usually mild and transient. Notify your clinic if the site becomes increasingly painful, red, warm, swollen, starts to discharge, or develops a fever, because these can indicate a local infection that requires evaluation.
- Implant visibility and palpability: In some patients, the implant may remain palpable or visible under the skin for some weeks after insertion and in occasional cases longer than expected. If an implant has not resorbed or has been felt for more than 3 months, tell your clinic so they can evaluate the site and consider whether surgical removal is required.
- Darkening of the skin and freckles: A deeper tan, especially on sun-exposed areas, is an expected pharmacodynamic effect. Some patients develop new freckles (ephelides) or increased prominence of existing moles. These changes usually fade some months after the last implant, but persistent lesions should be assessed dermatologically.
- General infections and wound healing: Like any minor surgical procedure, implant insertion can occasionally be followed by local infection. Keep the insertion site clean and dry for 48 hours after implantation and follow any specific aftercare instructions given by your clinic.
Your specialist team will carry out baseline and periodic assessments, including clinical examination, blood tests where indicated, and skin surveillance, to ensure that treatment remains safe for you over time.
Other Medications
Tell your doctor about all medicines you are currently taking, have recently taken, or are planning to take, including prescription medicines, over-the-counter products, herbal and dietary supplements, and vitamins. Particular care is needed with medicines that affect blood clotting or the immune system, and with other treatments that can influence pigmentation.
Pregnancy and Breastfeeding
There are no adequate and well-controlled studies of SCENESSE in pregnant women. Animal reproductive toxicology studies with afamelanotide have not demonstrated clear adverse effects on embryo-fetal development at clinically relevant exposures, but the data are limited. As a precaution, SCENESSE is not recommended during pregnancy unless the expected clinical benefit for the mother clearly outweighs any potential risk to the developing child. Women of childbearing potential should use effective contraception during treatment.
It is not known whether afamelanotide is excreted in human breast milk. A risk to the breastfed infant cannot be excluded. Use of SCENESSE during breastfeeding should generally be avoided. If breastfeeding is important to you, discuss the options with your specialist team and your obstetrician or paediatrician.
If you become pregnant during treatment, let your specialist know as soon as possible. They will review your options and determine whether the next scheduled implant should be postponed.
Driving and Operating Machinery
SCENESSE has no or negligible influence on the ability to drive or use machines. However, some patients report fatigue or headache, particularly in the first days after implantation. If you notice such symptoms, wait until they have resolved before driving or operating machinery.
Important Information About Ingredients
SCENESSE is a solid, sterile, rod-shaped implant approximately 1.45 cm in length and 1.5 mm in diameter. It contains the active substance afamelanotide in a biodegradable polymer matrix (poly(D,L-lactide-co-glycolide)) that slowly releases the medicine over approximately two months. The implant does not contain preservatives, sodium or gluten.
How Does SCENESSE Interact with Other Drugs?
Formal clinical pharmacokinetic interaction studies with afamelanotide are limited because plasma concentrations after subcutaneous implantation are low and transient. Available information comes from clinical trials, post-marketing reports, and general pharmacological reasoning. Despite the low systemic exposure, several classes of medication can practically influence how SCENESSE is experienced or tolerated, and should therefore be reviewed before each implant.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Oral anticoagulants (e.g., warfarin, apixaban, rivaroxaban, dabigatran) | Increased risk of bleeding and bruising at the implant site | Review anticoagulation before implantation; coordinate timing and consider local compression; do not interrupt anticoagulation without a formal risk assessment |
| Antiplatelet agents (e.g., acetylsalicylic acid, clopidogrel, ticagrelor) | Greater risk of haematoma formation at the insertion site | Use meticulous implantation technique; consider post-procedure compression; usually continue therapy per cardiology advice |
| Systemic immunosuppressants (e.g., ciclosporin, tacrolimus, mycophenolate, biologics) | Possible increase in infection risk at the implant site; unknown effect on pigmentation response | Use with caution; closer monitoring for local or systemic infection and for skin lesions |
| Photosensitising medications (e.g., some tetracyclines, sulfonamides, amiodarone, certain retinoids) | Additional photosensitivity on top of EPP; no direct pharmacokinetic interaction | Inform prescribing physicians about EPP; balance need for these drugs against phototoxicity risk |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| NSAIDs (e.g., ibuprofen, naproxen, diclofenac) | Slight increase in bruising risk at implant site; useful for pain or headache after implantation | Usually compatible; simple analgesics such as paracetamol may be preferred immediately after implantation |
| Systemic corticosteroids (oral or high-dose inhaled) | May influence skin integrity and wound healing; possible interaction with melanocyte response | Continue as prescribed but ensure the specialist is aware; monitor implant site healing |
| Hormonal contraceptives and hormone replacement therapy | Both melanocortin and sex-steroid pathways can influence pigmentation; clinical significance unclear | Usually safe; report any significant new pigmentation patterns such as chloasma-like changes |
| Vaccines | No known pharmacokinetic interaction; routine vaccination can be administered | Schedule vaccinations to avoid the injection site chosen for the SCENESSE implant |
Because the list above cannot cover every possible combination, always inform any clinician who prescribes for you – including your GP, dentist, and pharmacist – that you receive SCENESSE and carry a list of your current medications when visiting new healthcare providers. Your specialist porphyria centre should coordinate medication reviews, particularly around the time of each implant.
What Is the Correct Dosage of SCENESSE?
SCENESSE is always administered by a doctor who has completed the manufacturer's specific training programme and is authorised to perform implantation, usually within an accredited porphyria or dermatology centre. You do not handle or inject the medicine yourself. The dose, schedule and exact timing of implants are planned individually with your specialist team, taking into account local climate, your usual outdoor activities, and the season.
Adults
Standard Adult Dosing
Indication: Prevention of phototoxicity in adults with confirmed erythropoietic protoporphyria (EPP)
Dose: One 16 mg rod-shaped subcutaneous implant
Schedule: One implant every 2 months during anticipated increased sun exposure
Maximum: Up to 4 implants per 12-month period
Timing: The first implant of a season is typically placed approximately 10 days before the expected start of increased sun exposure (for example, in early spring in temperate climates), to allow time for eumelanin production to increase.
Children and Adolescents
SCENESSE is currently authorised only for use in adults. The safety and efficacy of afamelanotide in children and adolescents below 18 years of age have not been established in adequately designed trials, and routine use in this age group is not recommended. Clinical research is ongoing to explore use in paediatric EPP. If you are the parent or carer of a young person with EPP, your specialist porphyria centre can discuss alternative strategies and advise whether participation in a clinical trial might be appropriate.
Elderly Patients
There is limited clinical experience with SCENESSE in patients aged 70 years or older. No specific dose adjustment is currently recommended based on age alone, but treatment decisions should take into account individual health status, comorbidities (particularly cardiovascular and renal disease), concomitant medications, and the overall balance between expected benefit and risks of repeated implant procedures.
Missed or Delayed Implant
If you miss a scheduled implant appointment, contact your specialist centre as soon as possible to arrange a new one. The pharmacodynamic effect of afamelanotide (increased epidermal eumelanin) wanes over approximately two months, so delays may result in a reduction in the level of photoprotection achieved. If several months have elapsed since your last implant, your clinician may recommend starting with a single implant approximately 10 days before your next expected sun exposure rather than attempting to “catch up” with multiple implants in a short period.
Overdose
Overdose of SCENESSE is extremely unlikely because each implant is delivered as a single pre-manufactured unit by a trained clinician and the maximum authorised dose is four implants per year. In the unlikely event of accidental overdose (for example, implantation of more than one implant at a single visit without clinical indication), increased or more extensive skin darkening, prolonged implant-site reactions, fatigue and nausea could potentially occur. There is no specific antidote for afamelanotide. Management would be supportive and would include removal of any remaining implants by a qualified physician, monitoring of vital signs, symptomatic treatment, and close dermatological follow-up.
How SCENESSE Is Given
The implant is supplied in a sterile, single-use pre-loaded applicator. Before implantation, the chosen area of skin, usually above the anterior supra-iliac crest (the upper hip area), is cleaned and infiltrated with a small amount of local anaesthetic. The clinician then inserts the applicator needle just beneath the skin and deposits the solid implant into the subcutaneous fat. The needle is withdrawn and the site is covered with a sterile dressing, which is typically kept in place for 24 hours. The procedure usually takes only a few minutes and most patients experience only minor discomfort.
After implantation, patients are generally observed for at least 30 minutes for any immediate reaction. The dressing can be removed the following day, and the site should be kept clean and dry until healing is complete, usually within a week. Some patients are aware of a small firm lump at the implant site for the first few weeks; this is normal and typically resolves as the biodegradable polymer matrix is slowly resorbed.
SCENESSE is prepared and administered exclusively by trained healthcare professionals in an accredited porphyria centre or specialist dermatology clinic. You will not self-administer the implant at home. Each dose is carefully documented and reported to national pharmacovigilance systems and, in many countries, to a mandatory patient registry.
What Are the Side Effects of SCENESSE?
Like all medicines, SCENESSE can cause side effects, although not all patients experience them. The most frequent events reported in clinical trials and post-marketing experience are described below, organised according to the standard European Medicines Agency frequency categories. The list is based on the EMA Summary of Product Characteristics, the FDA prescribing information, and data from long-term disease registries.
Implant-Site and Procedure-Related Reactions
Reactions at the site of implantation are common and are usually mild or moderate. They can include pain, bruising, erythema, swelling, hyperpigmentation, tenderness, pruritus, warmth, or a small haematoma. Most resolve within a few days to a few weeks without specific treatment. In rare cases the implant can become palpable for longer than expected, extrude through the skin, or become infected; in such situations, contact your specialist team promptly for assessment.
Side Effects of SCENESSE Therapy
Very Common
May affect more than 1 in 10 people
- Nausea
- Headache
- Fatigue and general weakness
- Back pain
- Implant-site reactions (pain, erythema, hyperpigmentation, bruising, pruritus)
- Skin hyperpigmentation (darkening of the skin)
- New or more prominent freckles (ephelides)
- Upper respiratory tract infection
Common
May affect up to 1 in 10 people
- Dizziness
- Drowsiness or sleep disturbance
- Flushing or hot flushes
- Musculoskeletal pain (neck pain, myalgia, joint pain)
- Abdominal pain or discomfort
- Diarrhoea
- Decreased appetite
- Increased appetite
- Weight changes
- Pigmentation changes on lips, gums, tongue or other mucosal areas
- New melanocytic naevi (moles) or enlargement of existing naevi
- Acne or skin eruption
- Erythema
- Influenza-like illness
Uncommon
May affect up to 1 in 100 people
- Migraine
- Palpitations or tachycardia
- Transient increase in blood pressure
- Dysphonia (voice changes)
- Nasal congestion
- Vomiting
- Abdominal cramping
- Constipation
- Raised liver enzymes
- Implant-site infection or cellulitis
- Extrusion or late resorption of the implant
- Hypersensitivity reactions (rash, pruritus)
Rare
May affect up to 1 in 1,000 people
- Severe hypersensitivity or anaphylactoid reactions
- Severe local wound-healing problems
- Significant mood changes, anxiety or depression
- Syncope (fainting) related to the procedure
Not Known
Frequency cannot be estimated from available data
- Development of new pigmented lesions that require dermatological evaluation
- Long-term effects of repeated implantation over many years (under ongoing surveillance in disease registries)
What to Do if You Experience Side Effects
Most side effects of SCENESSE are mild and settle within hours or days. For common events such as headache, nausea or fatigue, simple measures (rest, hydration, paracetamol at recommended doses) are often sufficient. However, certain symptoms warrant prompt medical attention:
- Sudden widespread rash, difficulty breathing, facial or throat swelling, or dizziness – possible severe allergic reaction: seek emergency care.
- Fever, spreading redness, pus, or increasing pain at the implant site – possible infection: contact your specialist or primary care doctor urgently.
- A new or changing mole or pigmented lesion, particularly one that is asymmetric, has irregular borders, varies in colour, is larger than about 6 mm, or changes over time – arrange dermatological review promptly.
- Persistent severe mood changes, depression or anxiety not previously present – discuss with your doctor.
If you experience any side effects, including any not listed here, tell your doctor, pharmacist or nurse. You can also report suspected side effects directly to your national pharmacovigilance authority (for example, the Yellow Card Scheme in the United Kingdom, MedWatch in the United States, or the EMA-coordinated EudraVigilance system in the European Union). Reporting helps refine understanding of the benefit-risk profile of SCENESSE, particularly for a medicine approved under exceptional circumstances.
How Should SCENESSE Be Stored?
Because SCENESSE is a hospital-administered implant, storage is managed entirely by the specialist centre and its pharmacy. You do not need to keep SCENESSE at home or handle it yourself. However, if you are curious about the storage conditions that ensure the quality of the product, the key requirements are summarised below.
- Temperature: Store in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Do not freeze.
- Packaging: Keep the implant in its sealed primary container and outer carton until the moment of use to protect from light and contamination.
- Expiry date: Do not use after the expiry date printed on the carton and primary packaging. The expiry date refers to the last day of that month.
- Inspection: Before implantation, the clinician visually inspects the implant and applicator for any signs of damage or discoloration. A product that appears abnormal is not used.
- Child safety: As with all medicines, SCENESSE is kept out of reach and sight of children and unauthorised personnel within the clinical pharmacy environment.
Any unused SCENESSE product is disposed of in accordance with local pharmaceutical waste regulations. It must not be discarded in household waste or wastewater. This protects both the environment and the general public from unintentional exposure to prescription medicines.
What Does SCENESSE Contain?
Active Substance
The active substance is afamelanotide (INN). Afamelanotide is a synthetic tridecapeptide, more specifically [Nle4, D-Phe7]-alpha-melanocyte-stimulating hormone, manufactured by solid-phase peptide synthesis. In SCENESSE it is present as afamelanotide acetate. Each single-use implant contains 16 mg of afamelanotide (expressed as the free peptide), which is released gradually into the subcutaneous tissue over approximately two months after implantation.
Inactive Ingredients (Excipients)
- Poly(D,L-lactide-co-glycolide) – the biodegradable polymer matrix that controls the slow release of afamelanotide and is fully resorbed by the body over time.
SCENESSE does not contain lactose, sodium, gluten, alcohol, preservatives or animal-derived components.
Appearance
SCENESSE is a solid, off-white to pale yellow rod-shaped implant approximately 1.45 cm in length and 1.5 mm in diameter, pre-loaded in a sterile, single-use applicator. Each pack contains one implant ready for immediate subcutaneous insertion by a trained clinician.
Marketing Authorisation Holder and Manufacturer
SCENESSE is developed and marketed by Clinuvel Pharmaceuticals Ltd, an Australian biopharmaceutical company specialising in melanocortin science and rare photoprotection disorders. In the European Union and the United Kingdom, the marketing authorisation is held by Clinuvel (UK) Limited. Detailed manufacturer and batch information is printed on every outer carton and verified by your specialist centre before each implantation.
Frequently Asked Questions About SCENESSE
SCENESSE (afamelanotide) is used to prevent phototoxic reactions in adults with a confirmed diagnosis of erythropoietic protoporphyria (EPP). EPP is a rare inherited metabolic disorder in which protoporphyrin IX accumulates in the skin and causes extremely painful reactions to visible and ultraviolet light. SCENESSE is the first medicine specifically approved for EPP and works by increasing the amount of eumelanin, the dark photoprotective form of melanin, in the skin.
Each 16 mg SCENESSE implant releases afamelanotide gradually over approximately two months. Pharmacodynamic studies using melanin index measurements show that skin eumelanin levels increase within a few days of implantation, peak during the weeks that follow, and slowly return toward baseline over several months. To maintain a useful level of photoprotection during sunny periods, one implant is generally given every two months, for a maximum of four implants in any 12-month period.
No. SCENESSE increases the threshold for phototoxicity but does not eliminate the underlying EPP. Patients must continue with behavioural sun avoidance, protective clothing such as long sleeves and wide-brimmed hats, tinted glasses where appropriate, and physical sunblocks designed to reduce exposure to visible light. The goal of SCENESSE is to allow a more normal outdoor life alongside usual sun protection, not to enable unrestricted exposure to bright sunlight.
SCENESSE should not be confused with unlicensed melanotan products sometimes sold illicitly online or in gyms as “tanning injections”. Those illegal preparations are unregulated, of unknown composition and purity, and have been linked to serious harm including severe allergic reactions, dangerous rises in blood pressure, and changes in pigmented skin lesions. SCENESSE, in contrast, is a prescription-only, quality-controlled medicinal product, approved under strict regulatory oversight for the specific treatment of adult EPP and administered only by trained specialists.
Because SCENESSE stimulates melanocytes, the cells from which moles and melanoma arise, regular skin surveillance is mandatory during treatment. A full-body dermatological examination is recommended every 6 months, with more frequent review in patients who have a personal or family history of skin cancer or many atypical moles. Baseline total body photography can help to document existing lesions so that changes can be detected early. Tell your clinic promptly about any new or changing mole, persistent lesion, or area of skin that looks different from surrounding areas.
Randomised controlled trials (CUV029, CUV030, CUV039) and long-term observational data show that SCENESSE substantially increases the time that patients with EPP can spend in direct or indirect sunlight without a phototoxic reaction, and reduces both the number and severity of painful episodes. Patients typically report significantly improved quality-of-life scores, greater ability to work and engage in social activities, and reduced emotional burden from the disease. SCENESSE does not, however, correct the underlying enzyme defect, and individual responses vary; your specialist will review your personal outcomes and adjust your overall management plan as needed.
References
- European Medicines Agency (EMA). SCENESSE (afamelanotide) – Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR.
- U.S. Food and Drug Administration (FDA). SCENESSE (afamelanotide) implant Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373(1):48–59. doi:10.1056/NEJMoa1411481.
- Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601–1612.
- Wensink D, Wagenmakers M, Barman-Aksoezen J, et al. Association of afamelanotide with improved outcomes in patients with erythropoietic protoporphyria in clinical practice. JAMA Dermatol. 2020;156(5):570–575.
- Lala SM, Naik H, Balwani M. Diagnostic delay in erythropoietic protoporphyria. J Pediatr. 2018;202:320–323.e2.
- European Porphyria Network (EPNET). Clinical Management of Erythropoietic Protoporphyria and X-linked Protoporphyria – Consensus Document. Updated 2024.
- British Porphyria Association. Information and Clinical Guidance for Erythropoietic Protoporphyria (EPP). Updated 2024.
- Balwani M, Bloomer JR, Desnick RJ; Porphyrias Consortium of the NIH Rare Diseases Clinical Research Network. Erythropoietic Protoporphyria, Autosomal Recessive. In: Adam MP, et al., eds. GeneReviews. Seattle: University of Washington; 2023.
- Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clin Pharmacokinet. 2017;56(8):815–823.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in dermatology, photodermatology, porphyria care and clinical pharmacology.
Medical Content
iMedic Dermatology Editorial Team – specialist physicians in dermatology and photodermatology with clinical experience in rare pigmentation and porphyria disorders
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, EPNET and British Porphyria Association guidance
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in peptide therapeutics, drug interactions, and long-term pharmacovigilance
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.